Non-cystic Fibrosis Bronchiectasis Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	400 Pages	BlueWeave Consulting	August, 2023	BLWC18132168

Best Price Guarantee
Price	from $4,850
Length	400 Pages
Publisher	BlueWeave Consulting
Published Date	August, 2023
SKU	BLWC18132168

Non-cystic Fibrosis Bronchiectasis Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Treatment (Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics); By Type (Intravenous, Oral); By Diagnosis (CT Scan, Bronchoscopy, Chest X-Ray, Lung Function, Sputum Culture Test, Blood Tests); By End User (Clinic, Hospital); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Global Non-cystic Fibrosis Bronchiectasis Market Size Set to Touch USD 1.3 Billion by 2029

Global non-cystic fibrosis bronchiectasis market is flourishing because of the rising prevalence of non-cystic fibrosis bronchiectasis, rapidly aging world population and its higher susceptibility to respiratory diseases, ongoing advancements in diagnostic technologies, and growing awareness and early diagnosis initiatives.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global non-cystic fibrosis bronchiectasis market size at USD 0.94 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global non-cystic fibrosis bronchiectasis market size to grow at a CAGR of 5.55% reaching a value of USD 1.298 billion by 2029. Major growth drivers for the global non-cystic fibrosis bronchiectasis market include an increasing prevalence of chronic diseases, coupled with a rising healthcare expenditure and growing government initiatives. Advancements in treatment options and growing awareness among the general population and healthcare professionals about bronchiectasis symptoms have led to early diagnosis and improved patient management. Also, the market's growth is notably influenced by rising healthcare spending, particularly in emerging economies, which has facilitated better access to diagnosis and treatment for bronchiectasis patients. The rise in research and development activities and the potential opportunities presented by emerging markets are expected to further propel the market's development during the forecast period. However, limited treatment options and lack of disease-specific therapies, challenges in disease management and patient adherence, and the high cost of treatment and healthcare burden are anticipated to restrain the overall market growth during the period in analysis.

Global Non-cystic Fibrosis Bronchiectasis Market – Overview

The global non-cystic fibrosis bronchiectasis market refers to the worldwide industry involved in the diagnosis, treatment, and management of non-cystic fibrosis bronchiectasis, a chronic respiratory condition. Bronchiectasis is characterized by permanent dilation of the bronchi, leading to recurrent respiratory infections and impaired lung function. Unlike cystic fibrosis-related bronchiectasis, non-cystic fibrosis bronchiectasis is not caused by the genetic disorder cystic fibrosis. The market encompasses various healthcare stakeholders, including pharmaceutical companies, medical device manufacturers, healthcare providers, and research institutions, all contributing to the development of innovative therapies, medications, and diagnostic tools to address the challenges posed by non-cystic fibrosis bronchiectasis and improve patients' quality of life.

Impact of COVID-19 on Global Non-cystic Fibrosis Bronchiectasis Market

COVID-19 pandemic adversely affected the global non-cystic fibrosis bronchiectasis market. During the pandemic, healthcare systems were overwhelmed with managing COVID-19 patients, leading to a reduced focus on non-emergency conditions like bronchiectasis. Patients with respiratory conditions faced challenges in accessing healthcare facilities and adhering to treatment regimens due to restrictions and safety concerns. Also, disruptions in the supply chain and clinical trials affected the availability of treatments and research activities. However, with the gradual containment of the pandemic, the market is expected to recover as healthcare systems restore non-emergency services, and efforts to improve respiratory care continue.

Global Non-cystic Fibrosis Bronchiectasis Market – By End User

On the basis of end user, the global non-cystic fibrosis bronchiectasis market is bifurcated into Clinic and Hospital segments. The hospital segment held a higher market share by end-users. Hospitals are major healthcare centers where patients with respiratory conditions like non-cystic fibrosis bronchiectasis often seek diagnosis, treatment, and management. Hospitals typically have advanced medical facilities, equipment, and specialized healthcare professionals, making them capable of providing comprehensive care for bronchiectasis patients. Also, non-cystic fibrosis bronchiectasis may require specialized diagnostic tests and treatments, such as CT scans, bronchoscopies, and lung function tests, which are readily available in hospitals. The hospital setting also allows for closer monitoring of patients and immediate intervention in case of complications.

Competitive Landscape

Major players operating in the global non-cystic fibrosis bronchiectasis market include Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals Inc., Insmed Incorporated, and Bayer AG. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Non-cystic Fibrosis Bronchiectasis Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Non-cystic Fibrosis Bronchiectasis Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

1. Research Framework: 1.1. Research Objective; 1.2. Product Overview; 1.3. Market Segmentation
2. Executive Summary
3. Global Non-cystic Fibrosis Bronchiectasis Market Insights: 3.1. Industry Value Chain Analysis; 3.2. DROC Analysis; 3.2.1. Growth Drivers; 3.2.1.1. Increasing Prevalence of Non-Cystic Fibrosis Bronchiectasis; 3.2.1.2. Aging Population and Higher Susceptibility to Respiratory Diseases; 3.2.1.3. Advancements in Diagnostic Technologies; 3.2.1.4. Growing Awareness and Early Diagnosis Initiatives; 3.2.2. Restraints; 3.2.2.1. Limited Treatment Options and Lack of Disease-Specific Therapies; 3.2.2.2. Challenges in Disease Management and Patient Adherence; 3.2.2.3. High Cost of Treatment and Healthcare Burden; 3.2.3. Opportunities; 3.2.3.1. Rising Demand for Personalized Medicine and Precision Treatment Approaches; 3.2.3.2. Increasing Healthcare Expenditure and Infrastructure Development; 3.2.4. Challenges; 3.2.4.1. Complex Disease Pathophysiology and Heterogeneity; 3.2.4.2. Lack of Consensus on Clinical Management Guidelines; 3.3. Technological Advancements/Recent Developments; 3.4. Regulatory Framework; 3.5. Porter’s Five Forces Analysis; 3.5.1. Bargaining Power of Suppliers; 3.5.2. Bargaining Power of Buyers; 3.5.3. Threat of New Entrants; 3.5.4. Threat of Substitutes; 3.5.5. Intensity of Rivalry
4. Global Non-cystic Fibrosis Bronchiectasis Market Overview: 4.1. Market Size & Forecast by Value, 2019–2029; 4.1.1. By Value (USD Billion); 4.2. Market Share & Forecast; 4.2.1. By Treatment; 4.2.1.1. Surgery; 4.2.1.2. Physiotherapy; 4.2.1.3. Vaccination; 4.2.1.4. Airway Pharmacotherapy; 4.2.1.5. Antibiotics; 4.2.1.6. Others; 4.2.2. By Type; 4.2.2.1. Intravenous; 4.2.2.2. Oral; 4.2.2.3. Others; 4.2.3. By Diagnosis; 4.2.3.1. CT scan; 4.2.3.2. Bronchoscopy; 4.2.3.3. Chest X-Ray; 4.2.3.4. Lung Function; 4.2.3.5. Sputum Culture Test; 4.2.3.6. Blood Tests; 4.2.3.7. Others; 4.2.4. By End User; 4.2.4.1. Clinic; 4.2.4.2. Hospital; 4.2.4.3. Others; 4.2.5. By Region; 4.2.5.1. North America; 4.2.5.2. Europe; 4.2.5.3. Asia Pacific (APAC); 4.2.5.4. Latin America (LATAM); 4.2.5.5. Middle East and Africa (MEA)
5. North America Non-cystic Fibrosis Bronchiectasis Market: 5.1. Market Size & Forecast by Value, 2019–2029; 5.1.1. By Value (USD Billion); 5.2. Market Share & Forecast; 5.2.1. By Treatment; 5.2.2. By Type; 5.2.3. By Diagnosis; 5.2.4. By End User; 5.2.5. By Country; 5.2.5.1. United States; 5.2.5.1.1. By Treatment; 5.2.5.1.2. By Type; 5.2.5.1.3. By Diagnosis; 5.2.5.1.4. By End User; 5.2.5.2. Canada; 5.2.5.2.1. By Treatment; 5.2.5.2.2. By Type; 5.2.5.2.3. By Diagnosis; 5.2.5.2.4. By End User
6. Europe Non-cystic Fibrosis Bronchiectasis Market: 6.1. Market Size & Forecast by Value, 2019–2029; 6.1.1. By Value (USD Billion); 6.2. Market Share & Forecast; 6.2.1. By Treatment; 6.2.2. By Type; 6.2.3. By Diagnosis; 6.2.4. By End User; 6.2.5. By Country; 6.2.5.1. Germany; 6.2.5.1.1. By Treatment; 6.2.5.1.2. By Type; 6.2.5.1.3. By Diagnosis; 6.2.5.1.4. By End User; 6.2.5.2. United Kingdom; 6.2.5.2.1. By Treatment; 6.2.5.2.2. By Type; 6.2.5.2.3. By Diagnosis; 6.2.5.2.4. By End User; 6.2.5.3. Italy; 6.2.5.3.1. By Treatment; 6.2.5.3.2. By Type; 6.2.5.3.3. By Diagnosis; 6.2.5.3.4. By End User; 6.2.5.4. France; 6.2.5.4.1. By Treatment; 6.2.5.4.2. By Type; 6.2.5.4.3. By Diagnosis; 6.2.5.4.4. By End User; 6.2.5.5. Spain; 6.2.5.5.1. By Treatment; 6.2.5.5.2. By Type; 6.2.5.5.3. By Diagnosis; 6.2.5.5.4. By End User; 6.2.5.6. The Netherlands; 6.2.5.6.1. By Treatment; 6.2.5.6.2. By Type; 6.2.5.6.3. By Diagnosis; 6.2.5.6.4. By End User; 6.2.5.7. Rest of Europe; 6.2.5.7.1. By Treatment; 6.2.5.7.2. By Type; 6.2.5.7.3. By Diagnosis; 6.2.5.7.4. By End User
7. Asia-Pacific Non-cystic Fibrosis Bronchiectasis Market: 7.1. Market Size & Forecast by Value, 2019–2029; 7.1.1. By Value (USD Billion); 7.2. Market Share & Forecast; 7.2.1. By Treatment; 7.2.2. By Type; 7.2.3. By Diagnosis; 7.2.4. By End User; 7.2.5. By Country; 7.2.5.1. China; 7.2.5.1.1. By Treatment; 7.2.5.1.2. By Type; 7.2.5.1.3. By Diagnosis; 7.2.5.1.4. By End User; 7.2.5.2. India; 7.2.5.2.1. By Treatment; 7.2.5.2.2. By Type; 7.2.5.2.3. By Diagnosis; 7.2.5.2.4. By End User; 7.2.5.3. Japan; 7.2.5.3.1. By Treatment; 7.2.5.3.2. By Type; 7.2.5.3.3. By Diagnosis; 7.2.5.3.4. By End User; 7.2.5.4. South Korea; 7.2.5.4.1. By Treatment; 7.2.5.4.2. By Type; 7.2.5.4.3. By Diagnosis; 7.2.5.4.4. By End User; 7.2.5.5. Australia & New Zealand; 7.2.5.5.1. By Treatment; 7.2.5.5.2. By Type; 7.2.5.5.3. By Diagnosis; 7.2.5.5.4. By End User; 7.2.5.6. Indonesia; 7.2.5.6.1. By Treatment; 7.2.5.6.2. By Type; 7.2.5.6.3. By Diagnosis; 7.2.5.6.4. By End User; 7.2.5.7. Malaysia; 7.2.5.7.1. By Treatment; 7.2.5.7.2. By Type; 7.2.5.7.3. By Diagnosis; 7.2.5.7.4. By End User; 7.2.5.8. Singapore; 7.2.5.8.1. By Treatment; 7.2.5.8.2. By Type; 7.2.5.8.3. By Diagnosis; 7.2.5.8.4. By End User; 7.2.5.9. Philippines; 7.2.5.9.1. By Treatment; 7.2.5.9.2. By Type; 7.2.5.9.3. By Diagnosis; 7.2.5.9.4. By End User; 7.2.5.10. Vietnam; 7.2.5.10.1. By Treatment; 7.2.5.10.2. By Type; 7.2.5.10.3. By Diagnosis; 7.2.5.10.4. By End User; 7.2.5.11. Rest of APAC; 7.2.5.11.1. By Treatment; 7.2.5.11.2. By Type; 7.2.5.11.3. By Diagnosis; 7.2.5.11.4. By End User
8. Latin America Non-cystic Fibrosis Bronchiectasis Market: 8.1. Market Size & Forecast by Value, 2019–2029; 8.1.1. By Value (USD Billion); 8.2. Market Share & Forecast; 8.2.1. By Treatment; 8.2.2. By Type; 8.2.3. By Diagnosis; 8.2.4. By End User; 8.2.5. By Country; 8.2.5.1. Brazil; 8.2.5.1.1. By Treatment; 8.2.5.1.2. By Type; 8.2.5.1.3. By Diagnosis; 8.2.5.1.4. By End User; 8.2.5.2. Mexico; 8.2.5.2.1. By Treatment; 8.2.5.2.2. By Type; 8.2.5.2.3. By Diagnosis; 8.2.5.2.4. By End User; 8.2.5.3. Argentina; 8.2.5.3.1. By Treatment; 8.2.5.3.2. By Type; 8.2.5.3.3. By Diagnosis; 8.2.5.3.4. By End User; 8.2.5.4. Peru; 8.2.5.4.1. By Treatment; 8.2.5.4.2. By Type; 8.2.5.4.3. By Diagnosis; 8.2.5.4.4. By End User; 8.2.5.4.5.; 8.2.5.5. Colombia; 8.2.5.5.1. By Treatment; 8.2.5.5.2. By Type; 8.2.5.5.3. By Diagnosis; 8.2.5.5.4. By End User; 8.2.5.6. Rest of LATAM; 8.2.5.6.1. By Treatment; 8.2.5.6.2. By Type; 8.2.5.6.3. By Diagnosis; 8.2.5.6.4. By End User
9. Middle East & Africa Non-cystic Fibrosis Bronchiectasis Market: 9.1. Market Size & Forecast by Value, 2019–2029; 9.1.1. By Value (USD Billion); 9.2. Market Share & Forecast; 9.2.1. By Treatment; 9.2.2. By Type; 9.2.3. By Diagnosis; 9.2.4. By End User; 9.2.5. By Country; 9.2.5.1. Saudi Arabia; 9.2.5.1.1. By Treatment; 9.2.5.1.2. By Type; 9.2.5.1.3. By Diagnosis; 9.2.5.1.4. By End User; 9.2.5.2. UAE; 9.2.5.2.1. By Treatment; 9.2.5.2.2. By Type; 9.2.5.2.3. By Diagnosis; 9.2.5.2.4. By End User; 9.2.5.3. Qatar; 9.2.5.3.1. By Treatment; 9.2.5.3.2. By Type; 9.2.5.3.3. By Diagnosis; 9.2.5.3.4. By End User; 9.2.5.4. Kuwait; 9.2.5.4.1. By Treatment; 9.2.5.4.2. By Type; 9.2.5.4.3. By Diagnosis; 9.2.5.4.4. By End User; 9.2.5.5. South Africa; 9.2.5.5.1. By Treatment; 9.2.5.5.2. By Type; 9.2.5.5.3. By Diagnosis; 9.2.5.5.4. By End User; 9.2.5.6. Nigeria; 9.2.5.6.1. By Treatment; 9.2.5.6.2. By Type; 9.2.5.6.3. By Diagnosis; 9.2.5.6.4. By End User; 9.2.5.7. Algeria; 9.2.5.7.1. By Treatment; 9.2.5.7.2. By Type; 9.2.5.7.3. By Diagnosis; 9.2.5.7.4. By End User; 9.2.5.8. Rest of MEA; 9.2.5.8.1. By Treatment; 9.2.5.8.2. By Type; 9.2.5.8.3. By Diagnosis; 9.2.5.8.4. By End User
10. Competitive Landscape: 10.1. List of Key Players and Their Offerings; 10.2. Global Non-cystic Fibrosis Bronchiectasis Company Market Share Analysis, 2022; 10.3. Competitive Benchmarking, By Operating Parameters; 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Covid-19 on Global Non-cystic Fibrosis Bronchiectasis Market
12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis): 12.1. Novartis AG; 12.2. Teva Pharmaceutical Industries Ltd.; 12.3. Mylan N.V.; 12.4. Pfizer Inc.; 12.5. GlaxoSmithKline plc; 12.6. AstraZeneca plc; 12.7. Boehringer Ingelheim GmbH; 12.8. Sunovion Pharmaceuticals Inc.; 12.9. Insmed Incorporated; 12.10. Bayer AG; 12.11. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology: 14.1. Qualitative Research; 14.1.1. Primary & Secondary Research; 14.2. Quantitative Research; 14.3. Market Breakdown & Data Triangulation; 14.3.1. Secondary Research; 14.3.2. Primary Research; 14.4. Breakdown of Primary Research Respondents, By Region; 14.5. Assumption & Limitation